IPCALAB.NS
Ipca Laboratories Limited
NSEINREQUITY
Healthcare
DELAYED
Last price
1,911.20
▲ 11.10 (0.58%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1,908.10
Prev close
1,900.10
Day high
1,922.00
Day low
1,889.10
Volume
193.75K
Market cap
$484.88B
P/E (TTM)
37.04
52W range
1,251.60 – 1,945.10
Day trading desk
Gap from prior close
+0.42%
Prior close 1,900.10
VWAP
1,908.02
+0.17% from price
Relative volume
0.47×
Quiet session
Session range
1.71%
1,889.70 – 1,922.00
Position in range
67%
Mid range
ATR (14D)
75.66
3.96% of price
Prior day high
1,928.40
PDH
Prior day low
1,880.40
PDL
Bid / ask spread
—
Quote not published
Session volume
187.97K
Avg 399.89K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+10.21%
+11.6%
1M
+7.90%
+4.2%
3M
+21.12%
+18.0%
6M
+30.56%
+19.5%
YTD
+34.70%
+22.4%
1Y
+38.11%
+18.1%
3Y
+111.79%
+37.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on IPCALAB.NS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
114.31M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Feb 16, 26 | Jain (Manish Kumar) Promoter |
SELL | 3.00K | $48.99K | Direct |
| Aug 22, 25 | Kothari (Pawan) UNREPORTED |
SELL | 2.22K | $35.92K | Direct |
| Aug 20, 25 | Kaygee Investments Pvt Ltd Promoter |
— | 56.34M | — | Direct |
| Aug 20, 25 | Mexin Medicaments Pvt Ltd Promoter |
— | 14.06K | — | Direct |
| Aug 20, 25 | Paschim Chemicals Pvt Ltd Promoter |
— | 10.17M | — | Direct |
| Dec 18, 24 | Chandurkar (Usha M) Promoter |
SELL | 4.00M | $70.66M | Direct |
| Sep 4, 24 | HDFC Trustee Company Ltd UNREPORTED |
— | 5.12M | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Chandurkar (Usha M) |
Promoter | 4.30M | Sale |
HDFC Trustee Company Ltd |
UNREPORTED | 22.93M | Acquisition |
Jain (Manish Kumar) |
Promoter | 20.27K | Sale |
Kaygee Investments Pvt Ltd |
Promoter | 64.67M | Acquisition |
Kothari (Pawan) |
UNREPORTED | 0 | Sale |
Mexin Medicaments Pvt Ltd |
Promoter | 0 | Sale |
Paschim Chemicals Pvt Ltd |
Promoter | 0 | Sale |
Fundamentals
Market cap$484.88B
Enterprise value$495.61B
Revenue (TTM)$101.26B
Gross profit$68.59B
EBITDA$22.55B
Net income$13.10B
EPS (TTM)$51.60
Free cash flow—
Total cash$11.96B
Total debt$8.09B
Book value / share$317.84
Shares outstanding253.70M
Float139.31M
Short % of float—
Dividend yield0.31%
Beta (5Y)0.04
Valuation & profitability ratios
Trailing P/E37.04
Forward P/E27.18
PEG ratio—
Price / sales—
Price / book6.01
EV / revenue4.89
EV / EBITDA21.98
Gross margin67.73%
Operating margin20.04%
Profit margin12.93%
Return on equity—
Return on assets—
Debt / equity8.49
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $95.63B | $88.55B | $76.22B | $62.07B | — | +8.0% |
| Operating revenue | $95.63B | $88.55B | $76.22B | $62.07B | — | +8.0% |
| Cost of revenue | $29.80B | $29.30B | $27.26B | $24.08B | — | +1.7% |
| Gross profit | $65.82B | $59.24B | $48.97B | $37.99B | — | +11.1% |
| Research & development | $1.17B | $805.40M | $718.30M | $461.30M | — | +44.9% |
| Selling, general & admin | $10.67B | $9.99B | $8.26B | $6.32B | — | +6.8% |
| Total operating expense | $49.52B | $45.68B | $39.62B | $30.95B | — | +8.4% |
| Operating income | $16.30B | $13.56B | $9.34B | $7.05B | — | +20.2% |
| Net interest income | -$473.70M | -$527.20M | -$778.20M | $311.60M | — | +10.1% |
| Pre-tax income | $15.73B | $11.31B | $8.43B | $7.45B | — | +39.0% |
| Tax provision | $3.81B | $3.44B | $3.13B | $2.53B | — | +10.9% |
| Net income | $11.41B | $7.38B | $5.47B | $4.71B | — | +54.7% |
| Net income to common | $11.41B | $7.38B | $5.47B | $4.71B | — | +54.7% |
| Basic EPS | — | 29.08 | 21.57 | 18.58 | 34.85 | — |
| Diluted EPS | — | 29.08 | 21.57 | 18.58 | 34.85 | — |
| EBIT | $16.48B | $12.15B | $9.80B | $7.90B | — | +35.6% |
| EBITDA | $20.66B | $16.13B | $13.37B | $10.52B | — | +28.1% |
| Basic shares | — | 253.70M | 253.70M | 253.70M | 253.70M | — |
| Diluted shares | — | 253.70M | 253.70M | 253.70M | 253.70M | — |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $4.37B | $1.67B | $2.09B | $12.58B | +161.5% |
| Cash & short-term investments | $11.96B | $11.05B | $8.52B | $21.79B | +8.2% |
| Accounts receivable | $20.14B | $18.84B | $16.87B | $9.89B | +6.9% |
| Inventory | $27.31B | $25.60B | $24.71B | $17.43B | +6.7% |
| Total current assets | $63.77B | $62.69B | $55.39B | $51.89B | +1.7% |
| Property, plant & equipment | $52.71B | $47.63B | $46.96B | $27.32B | +10.7% |
| Goodwill & intangibles | $1.98B | $2.03B | $2.33B | $1.97B | -2.8% |
| Total assets | $123.70B | $117.61B | $111.01B | $86.26B | +5.2% |
| Total current liabilities | $23.07B | $23.86B | $23.56B | $18.06B | -3.3% |
| Current debt | $5.95B | $7.58B | $8.07B | $8.06B | -21.6% |
| Long-term debt | $1.09B | $5.43B | $5.80B | $6.52B | -79.9% |
| Total debt | $8.09B | $13.63B | $14.38B | $14.81B | -40.7% |
| Total liabilities | $28.46B | $33.72B | $33.74B | $27.11B | -15.6% |
| Retained earnings | $66.28B | $55.31B | $48.99B | $44.04B | +19.8% |
| Shareholder equity | $80.64B | $69.48B | $63.32B | $58.42B | +16.1% |
| Working capital | $40.70B | $38.82B | $31.83B | $33.83B | +4.8% |
| Net tangible assets | $78.66B | $67.45B | $60.99B | $56.45B | +16.6% |
| Shares issued | 253.70M | 253.70M | 253.70M | 253.70M | 0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | $15.73B | $11.31B | $8.43B | $7.45B | +39.0% |
| Depreciation & amortisation | $4.18B | $3.98B | $3.57B | $2.62B | +5.1% |
| Stock-based compensation | $8.10M | $20.60M | $30.60M | $0 | -60.7% |
| Change in working capital | -$2.94B | -$1.76B | -$915.90M | $489.90M | -66.6% |
| Operating cash flow | $11.42B | $13.21B | $9.45B | $8.06B | -13.6% |
| Capital expenditure | -$6.56B | -$7.76B | -$4.11B | -$4.94B | +15.4% |
| Investing cash flow | -$2.47B | -$8.70B | -$12.92B | -$7.25B | +71.6% |
| Dividends paid | -$524.10M | -$1.01B | -$507.40M | -$1.01B | +48.4% |
| Financing cash flow | -$7.54B | -$2.83B | -$5.53B | $5.07B | -166.3% |
| Free cash flow | $4.86B | $5.46B | $5.33B | $3.11B | -10.9% |
| End cash position | $10.66B | $9.25B | $7.56B | $15.79B | +15.3% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $23.88B | $23.93B | $25.57B | $23.09B | $22.47B | -0.2% |
| Operating revenue | $23.88B | $23.93B | $25.57B | $23.09B | $22.47B | -0.2% |
| Cost of revenue | $6.92B | $6.58B | $7.82B | $6.92B | $7.08B | +5.1% |
| Gross profit | $16.97B | $17.35B | $17.75B | $16.17B | $15.38B | -2.2% |
| Total operating expense | $13.20B | $13.09B | $13.33B | $13.01B | $12.10B | +0.9% |
| Operating income | $3.77B | $4.26B | $4.42B | $3.16B | $3.29B | -11.5% |
| Net interest income | -$202.00M | -$176.20M | -$196.10M | -$185.10M | -$215.10M | -14.6% |
| Pre-tax income | $4.04B | $4.46B | $3.92B | $3.31B | $1.28B | -9.3% |
| Tax provision | $950.50M | $819.30M | $1.08B | $960.90M | $622.20M | +16.0% |
| Net income | $2.99B | $3.26B | $2.83B | $2.33B | $678.20M | -8.3% |
| Net income to common | $2.99B | $3.26B | $2.83B | $2.33B | $678.20M | -8.3% |
| Basic EPS | 11.79 | 12.86 | 11.14 | 9.19 | 2.67 | -8.3% |
| Diluted EPS | 11.79 | 12.86 | 11.14 | 9.19 | 2.67 | -8.3% |
| EBIT | $4.25B | $4.64B | $4.11B | $3.49B | $1.50B | -8.4% |
| EBITDA | $5.32B | $5.71B | $5.15B | $4.49B | $2.50B | -6.9% |
| Basic shares | 253.66M | 253.71M | 253.65M | 253.76M | 254.01M | -0.0% |
| Diluted shares | 253.66M | 253.71M | 253.65M | 253.76M | 254.01M | -0.0% |
| Line item | 2026-03-31 | 2025-09-30 | 2025-03-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $4.37B | $2.13B | $1.67B | +105.3% |
| Cash & short-term investments | $11.96B | $12.83B | $11.05B | -6.8% |
| Accounts receivable | $20.14B | $20.77B | $18.84B | -3.0% |
| Inventory | $27.31B | $25.16B | $25.60B | +8.6% |
| Total current assets | $63.77B | $62.52B | $62.69B | +2.0% |
| Property, plant & equipment | $52.71B | $49.45B | $47.63B | +6.6% |
| Goodwill & intangibles | $1.98B | $2.03B | $2.03B | -2.6% |
| Total assets | $123.70B | $122.63B | $117.61B | +0.9% |
| Total current liabilities | $23.07B | $25.37B | $23.86B | -9.1% |
| Current debt | $5.95B | $8.05B | $7.58B | -26.1% |
| Long-term debt | $1.09B | $4.00B | $5.43B | -72.7% |
| Total debt | $8.09B | $12.79B | $13.63B | -36.8% |
| Total liabilities | $28.46B | $33.97B | $33.72B | -16.2% |
| Retained earnings | $66.28B | — | $55.31B | — |
| Shareholder equity | $80.64B | $74.27B | $69.48B | +8.6% |
| Working capital | $40.70B | $37.14B | $38.82B | +9.6% |
| Net tangible assets | $78.66B | $72.24B | $67.45B | +8.9% |
| Shares issued | 253.70M | 253.70M | 253.70M | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 12.16 | 15.84 | +30.3% |
| Mar 2026 | 10.45 | 13.31 | +27.3% |
| Dec 2025 | 11.61 | 12.09 | +4.1% |
| Sep 2025 | 10.72 | 12.35 | +15.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $27.93B | +9.3% |
| Next quarter | — | — | $26.78B | +11.9% |
| Current year | 59.98 | 16 | $109.95B | +14.0% |
| Next year | 70.31 | 17 | $122.66B | +11.6% |
Analyst targets & ownership
Mean target$1,972.28
High target$2,190.00
Low target$1,731.00
Implied upside3.20%
Analyst count18
ConsensusSTRONG BUY
Strong buy / Buy4 / 11
Hold2
Sell / Strong sell0 / 0
Held by insiders45.06%
Held by institutions45.42%
Institutions holding80
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1,821.30
+4.94% from price
SMA 20
1,785.80
+7.02% from price
SMA 50
1,746.43
+9.43% from price
SMA 100
1,645.29
+16.16% from price
SMA 200
1,554.10
+22.98% from price
EMA 12
1,834.90
+4.16% from price
EMA 26
1,796.84
+6.36% from price
EMA 50
1,750.63
+9.17% from price
RSI (14)
64.5
Neutral
MACD (12,26,9)
38.05
Hist 16.46
ATR (14)
75.66
3.96% of price
Realised vol 30D
36.9%
Annualised
Bollinger upper
1,924.48
20, 2σ
Bollinger lower
1,647.12
20, 2σ
50 / 200 cross
Golden
1,746.43 vs 1,554.10
Trend bias
Above 200
+22.98%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.21
Less volatile than market
Correlation to SPY
-0.09
Largely independent
Realised vol 30D
36.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-12.0%
Peak to trough
Max drawdown 5Y
-48.8%
Peak to trough
ATR 14
75.66
3.96% of price
Beta (reported)
0.04
5Y monthly, from filing
Dividends & splits
Forward rate$6.00 / yr
Forward yield0.31%
5-year avg yield0.32%
Payout ratio3.87%
Ex-dividend dateAug 7, 2026
Next pay date—
Last split2:1
Split dateJan 10, 2022
Headlines
Cardinal Health's CEO Moved 124,529 Shares in Two Days. Here's What Long-Term Investors Should Know
Motley Fool · 12m ago
After Biggest One-Day Decline Since 2022, Is Walmart Stock a Buy?
Motley Fool · 22m ago
He Was Laid Off at 63 and Thought Social Security Ruled Out Unemployment. He Was Wrong.
24/7 Wall St. · 27m ago
A 22-year-old inherited $1.7 million after her mom's sudden death. These are the tax and IRS rules she needs to know now
Moneywise · 27m ago
Nvidia Reportedly Warns Top Customers of 15% Price Hikes on AI Servers
BeInCrypto · 28m ago
Bitcoin slips under $77,000 as rally boosts mining economics
Investing.com · 29m ago
Anthropic Could Outdo SpaceX With Its IPO. Here's How Much Investors Think It's Worth Right Now and Why.
Motley Fool · 32m ago
Billionaire David Tepper Has 16% of His $7.5 Billion Appaloosa Portfolio in Amazon Stock. Is It Still a Buy?
Motley Fool · 35m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.